Good, Elin http://orcid.org/0000-0002-3418-1706
Ochoa-Figueroa, Miguel
Ziegler, Magnus
Ressner, Marcus
Warntjes, Marcel
Dyverfeldt, Petter
Lubberink, Mark
Ahlström, Håkan
de Muinck, Ebo
Clinical trials referenced in this document:
Documents that mention this clinical trial
18Fluorodeoxyglucose uptake in relation to fat fraction and R2* in atherosclerotic plaques, using PET/MRI: a pilot study
https://doi.org/10.1038/s41598-021-93605-x
Funding for this research was provided by:
Henry och Ella Margareta Ståhls Stiftelse (LIO-748491)
Swedish Heart-Lung Foundation (20170492)
Linköping University
Article History
Received: 25 January 2021
Accepted: 24 June 2021
First Online: 9 July 2021
Competing interests
: Marcel Warntjes is a consultant for SyntheticMR AB, Linköping, Sweden, and he holds shares in this company. The fat fraction and R2* quantification software used in the study and reported in the current paper is a modification of software developed by Warntjes and commercialized by SyntheticMR AB. The software version used in the current study is not intended for commercial use, but Warntjes cannot exclude that it will benefit SyntheticMR AB at some point in the future. SyntheticMR AB has not funded or supported the current study in any way shape or form. Håkan Ahlström is one of four founders and part-time employee of Antaros Medical AB, Mölndal, Sweden. The remaining co-authors declare that they have no conflict of interest.